Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas
- PMID: 2990751
- DOI: 10.1007/BF00257535
Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas
Abstract
In all 63 patients were treated monthly with a combination of mitomycin, doxorubicin, and cisplatin, and 27 (43%) experienced objective regression of their advanced sarcomas during a 3-month trial. The observed regression rate is numerically higher than any previously observed at our institution.
References
MeSH terms
Substances
LinkOut - more resources
Medical